Precigen earnings release, May 13, 2026

Precigen, Inc. (PGEN) · Form 8-K, Item 2.02 · Filed · SEC filing

Precigen Reports First Quarter 2026 Financial Results and Business

Updates

GERMANTOWN, MD, May 13, 2026 – Precigen,

Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced first quarter 2026 financial results and business updates.

“We are thrilled with the strength of the

PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the US and work toward expanded market opportunities in additional geographies and the pediatric patient population,” said Helen Sabzevari, PhD, President and CEO of Precigen. “Looking ahead, we are excited to advance the next chapter of our AdenoVerse platform through the continued development of PRGN-2009 in HPV-associated cancers, and look forward to sharing more details on our broader pipeline progress later this year. We are also proud to once again collaborate with the Recurrent Respiratory Papillomatosis Foundation in recognizing RRP Awareness Day for the third consecutive year on June 11, reflecting our deep and long-standing commitment to the RRP community. This year's event carries particular significance as adult patients now have access to an approved treatment, PAPZIMEOS, for the first time in the more than 100-year history of this disease.”

“We are encouraged by the strong progress we are seeing as PAPZIMEOS continues to gain traction, with approximately 400 patients currently enrolled in the PAPZIMEOS patient hub, of which a noteworthy 25% are from the community setting,” said Phil Tennant, Chief Commercial Officer of Precigen. “We are focused on converting hub enrollment into treated patients, and we look forward to building on this progress in the second quarter and beyond as more sites become activated, the impact of the permanent J-code takes hold, and our targeted site support helps deliver a seamless journey to treatment.”

KEY PROGRAM HIGHLIGHTS

PAPZIMEOS™

: First-line

Standard of Care for the Treatment of Adults with RRP

PAPZIMEOS (zopapogene imadenovec-drba) is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against HPV 6 and HPV 11 proteins in patients with RRP. In August 2025, the US Food and Drug Administration (FDA) granted full approval of PAPZIMEOS with a broad label for the treatment of adults with RRP. PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP and the first treatment that addresses the root cause of RRP.

PAPZIMEOS is accessible to an estimated

297 million US lives, or over 90% of insured lives in the US, reflecting broad and growing payer support for the therapy.

PRGN-2009 AdenoVerse®

Immunotherapy in HPV-associated

Cancers

PRGN-2009 is an investigational AdenoVerse immunotherapy designed to activate the immune system to recognize and target HPV-associated cancers.

FINANCIAL HIGHLIGHTS

“We are pleased with the launch performance of PAPZIMEOS, recognizing $21.6 million of net revenue in the first full quarter of its launch.

In the second quarter of 2026, we are seeing continued strength in revenue growth from PAPZIMEOS,” said Harry Thomasian Jr., Chief

Financial Officer of Precigen. “As of March 31, 2026, the Company’s cash, cash equivalents, and investments totaled $56.7 million, which based on payment terms, did not include any collection of PAPZIMEOS related accounts receivable since launch of approximately

$25.7 million. Based on our current revenue outlook and present financial forecast, we continue to believe that our current cash position and anticipated cash to be received from PAPZIMEOS sales will fund operations through cash flow break-even by the end of 2026.

Our forecasted expenditures include additional investments to progress both clinical and pre-clinical assets.”

First Quarter 2026 Financial Results Compared to Prior Year Period

Total revenues increased by $21.9 million compared to the three months ended March 31, 2025. The significant increase in total revenues for the three months ended March 31, 2026 was due to the ramp up of commercial sales of PAPZIMEOS following its FDA approval in August 2025. Revenues related to the sale of PAPZIMEOS for the three months ended March 31, 2026 were $21.6 million. No PAPZIMEOS sales were recorded for the three months ended March 31, 2025, as the product had not yet been approved.

R&D expenses decreased by $4.8 million compared to the three months ended March 31, 2025, primarily due to the change in the accounting treatment of manufacturing costs as a result of the FDA approval of PAPZIMEOS.

Selling, general, and administrative (SG&A) expenses increased by $8.7 million compared to the three months ended March 31, 2025. This increase was primarily driven by commercial activities related to PAPZIMEOS following its FDA approval in August 2025.

Total other expense, net, decreased by $29.6 million compared to the three months ended March 31, 2025. This change was primarily attributable to the absence of a $32.5 million charge related to the increase in the fair value of warrant liabilities that was recorded in the prior-year period. The remaining change (an increase in other expense) primarily relates to an increase of $2.9 million in interest expenses related to long term debt that originated in the third quarter of 2025.

Net loss was $7.9 million, or $0.02 per basic and diluted share, for three months ended March 31, 2026, compared to a net loss of $54.2 million, or $0.18 per basic and diluted share, for the three months ended March 31, 2025.

###

Precigen: Advancing Medicine with Precision®

Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical... (truncated)fficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or

YouTube.

Trademarks

Precigen, PAPZIMEOS, AdenoVerse, and Advancing

Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking

Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited) (Amounts in thousands, except share Three Months Ended March 31, and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenuesProduct revenues, net21,828203
RevenuesService revenues1,4241,138
RevenuesTotal revenues23,2521,341
Operating ExpensesCost of products and services2,5591,100
Operating ExpensesResearch and development5,63810,478
Operating ExpensesSelling, general and administrative21,04912,359
Operating ExpensesTotal operating expenses29,24623,937
Operating ExpensesOperating loss-5,994-22,596
Other Income (Expense), NetChange in fair value of warrant liabilities-32,481
Other Income (Expense), NetInterest expense-2,908-1
Other Income (Expense), NetInterest income683918
Other Income (Expense), NetOther income, net2907
Other Income (Expense), NetTotal other income (expense), net-1,935-31,557
Other Income (Expense), NetLoss before income taxes-7,929-54,153
Other Income (Expense), NetNet loss-7,929-54,153
Net loss per shareNet loss per share, basic and diluted-0.02-0.18
Net loss per shareWeighted average shares outstanding, basic and diluted354,291,007293,879,653

Balance Sheet

March 31, 2026 — (Unaudited) (in thousands)

March 31, 2026December 31, 2025
Current assetsCash and cash equivalents7,48030,234
Current assetsShort-term investments48,76667,624
ReceivablesTrade, net26,4033,916
ReceivablesOther302446
ReceivablesInventory14,7259,581
ReceivablesPrepaid expenses and other3,9963,434
ReceivablesTotal current assets101,672115,235
ReceivablesLong-term investments4892,511
ReceivablesProperty, plant and equipment, net13,21913,758
ReceivablesIntangible assets, net2,8643,182
ReceivablesGoodwill15,23215,232
ReceivablesRight-of-use assets4,3694,679
ReceivablesOther assets782908
ReceivablesTotal assets138,627155,505
Current liabilitiesAccounts payable2,58911,985
Current liabilitiesAccrued compensation and benefits4,55610,199
Current liabilitiesOther accrued liabilities12,48110,993
Current liabilitiesIndemnification accruals2,476
Current liabilitiesDeferred revenue410517
Current liabilitiesCurrent portion of lease liabilities1,0681,136
Current liabilitiesTotal current liabilities21,10437,306
Current liabilitiesLong-term debt93,51993,174
Current liabilitiesLease liabilities, net of current portion3,6633,980
Current liabilitiesOther long-term liabilities106134
Current liabilitiesTotal liabilities118,392134,594
Shareholders' equityAdditional paid-in capital2,369,5292,362,252
Shareholders' equityAccumulated deficit-2,349,277-2,341,348
Shareholders' equityAccumulated other comprehensive (loss) income-177
Shareholders' equityTotal shareholders' equity20,23520,911
Shareholders' equityTotal liabilities and shareholders' equity138,627155,505
Full release

Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,”

“goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”

“future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company’s business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company’s ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company’s future financial and operational results including the Company’s ability to reach cash flow break-even, and the Company’s ability to commence clinical studies or complete ongoing clinical studies for the

Company’s clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:

Steven M. Harasym

Tel: +1 (202) 365-2563 investors@precigen.com

Media Contact:

Donelle M. Gregory press@precigen.com

Precigen, Inc. and Subsidiaries

Consolidated Balance Sheets

(Unaudited)

Precigen, Inc. and Subsidiaries

Consolidated Statement of Operations

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Precigen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.